NEW ORLEANS--(BUSINESS WIRE)--VGXI, Inc., a leading provider of DNA plasmid manufacturing and development services, announced today at the 2010 DNA Vaccines Conference the expansion of its state-of-the-art cGMP plasmid manufacturing facility in The Woodlands, TX. “This expansion nearly doubles the size of our current facility putting us in a much better position to meet the growing demand for our research and cGMP manufacturing services,” said Henry Hebel, COO.
While at the conference, Mr. Hebel will present a talk entitled Developing a Successful Contract Manufacturing Organization Partnership: A Case Study where he will discuss what to expect from a CMO and present examples of challenging projects successfully completed by VGXI.
The Company also announced the addition of DNA vaccine pioneer, Dr. David Weiner, Ph.D., to VGXI’s Scientific Advisory Board. Dr. Weiner currently serves as the Chairman of Inovio Biomedical’s Scientific Advisory Board and as a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania.
VGXI also announced the addition of Sandra Jones as Director of Validation and David Colvin as Key Account Manager. Ms. Jones comes to VGXI from Beckman-Coulter, Inc. where she was the Quality Assurance Engineering Supervisor and Calibration Manager. She has 17 years of experience in FDA regulated industries, including food, pharmaceutical and medical devices. She holds a BS in Chemical Engineering from Prairie View A&M University and an Executive Management Certification in Finance & Accounting from Cornell University.
Mr. Colvin joins VGXI from Merck & Co., where he was responsible for selling cardiovascular and diabetic medications to cardiologists, endocrinologists and primary care physicians. Prior to joining Merck in 2006, he was the co-founder of SYNTHEGEN, LLC, a biotechnology company that marketed reagents for genomics research. He holds a BS in Biochemistry from Texas A&M University and an Executive Certification in Finance & Accounting from Rice University.
About VGXI, Inc.
VGXI Inc. is a leading provider of DNA plasmid manufacturing and development services for DNA vaccine and gene therapy research. The Company has an outstanding track record of success in manufacturing plasmid products under cGMP conditions for client companies’ clinical studies in the US and Europe, and its cGMP and non-cGMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. The recently announced research and pre-clinical production services extend the range of high-quality, research grade materials utilizing the same efficient service. This rapid turnaround program provides consistent materials to build a reliable pre-clinical dataset.
Cautionary Factors That May Affect Future Results - Materials in this Web site contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.
Contact:
VGXI, Inc. David Colvin, 281-296-7300
